Search Within

Rachel Nicole Grisham

Formats
  1. Journal Article (80)
  2. Meeting Abstract (78)
  3. Review (9)
  4. Guidelines (3)
  5. Book Section (2)
  6. Editorial (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (175)
  2. GDMT, Medicine (175)
  3. Gynecologic Medicine Service (175)
  4. Gynecology Disease Management Team (175)
  5. Solid Tumor Oncology Division (175)
  6. Surgery (76)

More Groups

People
  1. Carol Aghajanian (87)
  2. Roisin O'Cearbhaill (68)
  3. Alexia Iasonos (63)
  4. Qin Zhou (56)
  5. Dennis Chi (52)
  6. Kara Long Roche (49)

More People

Years
  1. 2025 (13)
  2. 2024 (29)
  3. 2023 (26)
  4. 2022 (23)
  5. 2021 (12)
  6. 2020 (21)

More Years

Publications
  1. Gynecologic Oncology (49)
  2. Journal of Clinical Oncology (37)
  3. International Journal of Gynecological Cancer (28)
  4. Clinical Cancer Research (8)
  5. Cancer (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (50)
  2. American Society of Clinical Oncology (42)
  3. Lippincott Williams & Wilkins (30)
  4. American Association for Cancer Research (10)
  5. Wiley Blackwell (8)
  6. Nature Publishing Group (6)

More Publishers

Results (175)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transforming ovarian cancer care by targeting minimal residual disease
    Editorial

    Jazaeri, A. A.; Grisham, R.; Knisely, A.; Spranger, S.; Zamarin, D.; Hillman, R. T.; Lawson, B. C.; Burns, K. H.; Lee, S.; Westin, S. N.; more...
    Med (2023)

    Fulltext@MSK | Save
  • Molecular results and potential biomarkers identified from the phase 3 MILO/ENGOT-ov11 study of binimetinib versus physician choice of chemotherapy in recurrent low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Vergote, I.; Banerjee, S.; Drill, E.; Kalbacher, E.; Mirza, M. R.; Romero, I.; Vuylsteke, P.; Coleman, R. L.; Hilpert, F.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: A three-arm, randomized, controlled, open-label phase II study
    Journal Article

    Colombo, N.; Van Gorp, T.; Matulonis, U. A.; Oaknin, A.; Grisham, R. N.; Fleming, G. F.; Olawaiye, A. B.; Nguyen, D. D.; Greenstein, A. E.; Custodio, J. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Low-grade serous ovarian cancer: Expert consensus report on the state of the science
    Journal Article

    Grisham, R. N.; Slomovitz, B. M.; Andrews, N.; Banerjee, S.; Brown, J.; Carey, M. S.; Chui, H.; Coleman, R. L.; Fader, A. N.; Gaillard, S.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Banerjee, S. N.; Ring, K. L.; Van Nieuwenhuysen, E.; Fabbro, M.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Santin, A.; Clamp, A. R.; Moore, K. N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline variants in non- BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival
    Meeting Abstract

    Kahn, R. M.; Selenica, P.; Boerner, T.; Xiao, Y.; Sia, T.; Sheehan, M.; Zhou, Q.; Iasonos, A.; Grisham, R. N.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer
    Meeting Abstract

    Yap, T. A.; Elhaddad, A. M.; Grisham, R. N.; Hamm, J. T.; Marks, D. K.; Shapiro, G.; Le Corre, C.; Li, J.; Lin, T. T.; Liu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The highs and lows of serous ovarian cancer
    Review

    Grisham, R. N.; Manning-Geist, B. L.; Chui, M. H.
    Cancer (2023)

    Fulltext@MSK | Save
  • Somatic BAP1 loss in ovarian serous borderline tumor and recurrent low-grade serous carcinoma from a germline BAP1 mutation carrier
    Correspondence

    Chui, M. H.; Grisham, R. N.
    International Journal of Gynecological Pathology (2023)

    Fulltext@MSK | Save
  • Leave it in the past - Primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study
    Journal Article

    Sia, T. Y.; Manning-Geist, B. L.; Ehmann, S.; Lavery, J. A.; Luardo, C.; Praiss, A.; Iasonos, A.; Sonoda, Y.; Grisham, R. N.; Liu, Y. L.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save